SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Eris Lifesciences reports Profit after tax of Rs 693.48 Mln, in the March 2021 quarter

13 May 2021 Evaluate
The company witnessed a 11.32% growth in the revenue at Rs. 2568.49 millions for the quarter ended March 2021 as compared to Rs. 2307.37 millions during the year-ago period.A good growth in profit of 25.84% reported to Rs. 693.48  millions over Rs. 551.07 millions of corresponding previous quarter.Operating profit surged to 967.68 millions from the corresponding previous quarter of 724.44 millions.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202103 202003 % Var 202103 202003 % Var 202103 202003 % Var
Sales 2568.49 2307.37 11.32 11088.34 10202.31 8.68 11088.34 10202.31 8.68
Other Income 27.48 -7.97 -444.79 99.98 147.28 -32.12 99.98 147.28 -32.12
PBIDT 967.68 724.44 33.58 4273.12 3703.28 15.39 4273.12 3703.28 15.39
Interest 1.99 2.62 -24.05 7.78 18.54 -58.04 7.78 18.54 -58.04
PBDT 965.69 721.82 33.79 4265.34 3684.74 15.76 4265.34 3684.74 15.76
Depreciation 101.38 129.67 -21.82 376.40 448.82 -16.14 376.40 448.82 -16.14
PBT 864.31 592.15 45.96 3888.94 3235.92 20.18 3888.94 3235.92 20.18
TAX 170.83 41.08 315.85 382.89 323.18 18.48 382.89 323.18 18.48
Deferred Tax 4.72 -63.77 -107.40 -318.95 -251.74 26.70 -318.95 -251.74 26.70
PAT 693.48 551.07 25.84 3506.05 2912.74 20.37 3506.05 2912.74 20.37
Equity 135.78 135.78 0.00 135.78 135.78 0.00 135.78 135.78 0.00
PBIDTM(%) 37.68 31.40 20.00 38.54 36.30 6.17 38.54 36.30 6.17

Eris Lifesciences Share Price

1446.50 -18.90 (-1.29%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×